EICHORPublic-registry trials using ALLN-346 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
ALLN-346 appears in 1 registered trial Eichor's radar has found, sponsored by Allena Pharmaceuticals, the most recent registered as Phase 2, with a planned enrollment of 19. Registered timeline: 2022–2022. The registry holds 405 registered studies for Gout.
| Trial | Sponsor | Condition | Phase | Sites |
| Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease | Allena Pharmaceuticals | Hyperuricemia | PHASE2 | 17 |
| Status | Terminated · planned start 2022-09 |
| Primary completion | 2022-09 |
| Enrollment target | 19 participants |
| Design | Randomized · Parallel · Phase 2 · 2 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 17 listed in United States |
All fields verbatim from the ClinicalTrials.gov record for NCT04987294.
| First registered study | January 2020 — NCT04236219 (Allena Pharmaceuticals) |
| Registered studies matching this name | 5 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 405 registered studies for Gout. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Hyperuricemia studies · Weekly briefs
